Capital Management Corp VA lowered its stake in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 58.1% during the second quarter, Holdings Channel reports. The firm owned 61,030 shares of the biotechnology company’s stock after selling 84,510 shares during the period. Capital Management Corp VA’s holdings in Anika Therapeutics were worth $3,011,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in ANIK. Comerica Bank increased its position in shares of Anika Therapeutics by 4.9% in the fourth quarter. Comerica Bank now owns 15,834 shares of the biotechnology company’s stock valued at $792,000 after buying an additional 739 shares during the period. State Street Corp increased its position in shares of Anika Therapeutics by 3.2% in the fourth quarter. State Street Corp now owns 316,791 shares of the biotechnology company’s stock valued at $15,507,000 after buying an additional 9,917 shares during the period. FMR LLC purchased a new position in shares of Anika Therapeutics during the fourth quarter valued at about $1,772,000. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Anika Therapeutics by 176.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,812 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 2,432 shares during the period. Finally, Thrivent Financial for Lutherans increased its position in shares of Anika Therapeutics by 5.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,920 shares of the biotechnology company’s stock valued at $388,000 after buying an additional 390 shares during the period. 80.90% of the stock is owned by institutional investors.
Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) traded up 0.76% during midday trading on Monday, reaching $46.47. 75,267 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $47.03 and its 200 day moving average price is $47.10. The firm has a market capitalization of $680.97 million, a P/E ratio of 22.43 and a beta of 1.68. Anika Therapeutics Inc. has a 52-week low of $41.38 and a 52-week high of $53.50.
Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Wednesday, May 3rd. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.38 by $0.01. The business had revenue of $23.39 million for the quarter, compared to the consensus estimate of $23.89 million. Anika Therapeutics had a return on equity of 14.29% and a net margin of 29.81%. Anika Therapeutics’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.45 EPS. On average, equities research analysts anticipate that Anika Therapeutics Inc. will post $1.91 EPS for the current fiscal year.
WARNING: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/07/17/anika-therapeutics-inc-anik-shares-sold-by-capital-management-corp-va.html.
Separately, Zacks Investment Research downgraded shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, May 8th.
In related news, CEO Charles H. Sherwood sold 14,201 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $50.03, for a total value of $710,476.03. Following the transaction, the chief executive officer now owns 246,740 shares in the company, valued at $12,344,402.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffery S. Thompson sold 10,725 shares of the firm’s stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $47.39, for a total value of $508,257.75. Following the completion of the transaction, the director now owns 15,845 shares in the company, valued at approximately $750,894.55. The disclosure for this sale can be found here. 6.57% of the stock is currently owned by corporate insiders.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).
What are top analysts saying about Anika Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anika Therapeutics Inc. and related companies.